The latest studies in vision science research – from treating retinoblastoma to developing therapies for retinopathy
Aleksandra Jones | | Quick Read
Scientists from the Oklahoma Medical Research Foundation (OMRF) in Oklahoma City, have been studying the development of blood vessels, including one set that regresses and disappears in murine eyes after birth. The researchers discovered that down-regulation of a specific class of proteins called ETS transcription factors was responsible for this natural blood vessel loss in the eye. A compound called YK-4- 279 acts as an inhibitor of these ETS transcription factors and appeared to be particularly effective in low-flow vessels. The researchers decided to test the effectiveness of YK-4-279 in an oxygen-induced retinopathy mouse model that mimics human disease (including diabetic retinopathy and retinopathy of prematurity) and found: i) YK-4-279 reduced the abnormal neovascular tufts associated with the model and ii) the compound did not appear to affect healthy retinal vessels. Together, these discoveries point to the therapeutic potential of ETS transcription factor inhibitors (1).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine